Oliver Luxxe Assets LLC Increases Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Oliver Luxxe Assets LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 103.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,250 shares of the biopharmaceutical company's stock after acquiring an additional 35,225 shares during the period. Oliver Luxxe Assets LLC owned approximately 0.06% of Catalyst Pharmaceuticals worth $1,445,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 25.5% during the 4th quarter. CWA Asset Management Group LLC now owns 33,698 shares of the biopharmaceutical company's stock valued at $703,000 after acquiring an additional 6,853 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after purchasing an additional 33,888 shares during the last quarter. Franklin Resources Inc. grew its position in Catalyst Pharmaceuticals by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company's stock worth $1,221,000 after purchasing an additional 1,967 shares during the period. Sanctuary Advisors LLC purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $667,000. Finally, Hohimer Wealth Management LLC purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $329,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Down 3.3 %

NASDAQ CPRX traded down $0.66 on Tuesday, reaching $19.53. 1,754,125 shares of the stock were exchanged, compared to its average volume of 1,099,113. The firm has a market capitalization of $2.33 billion, a PE ratio of 16.55, a PEG ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a one year low of $13.12 and a one year high of $24.27. The company's 50-day simple moving average is $21.77 and its two-hundred day simple moving average is $19.83.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company's stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. Corporate insiders own 11.00% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on CPRX shares. Stephens started coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective for the company. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.